Interim report January - March 2018: High profitability and Time-lapse growth

First quarter:

  • Sales amounted to SEK 264 (244) million, corresponding to an increase of 8 percent in SEK. Sales growth was 8 percent in local currency and consisted in its entirety of organic growth.
  • Operating income before depreciation and amortisation (EBITDA) amounted to SEK 106 (95) million, corresponding to a margin of 40 (39) percent. Fluctuations in exchange rates positively impacted EBITDA by SEK 3 million.
  • Net income amounted to SEK 72 (60) million, which gave earnings per share of SEK 3.29 (2.73).
  • Acquisition of licensing rights to technology for embryo transfer.
  • Market approval for EmbryoScope in China.

Gothenburg, April 24, 2018
VITROLIFE AB (publ)
Thomas Axelsson, CEO

Report

Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14

This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 am CET on April 24, 2018.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.